Novelix Raises Funding Round

La Jolla-based Novelix Pharmaceuticals said this morning that it has raised a Series A-3 Preferred Stock financing for its biopharmaceuticals products. Amount and source of the funding was not disclosed. Novelix is developing proprietary small molecule drugs for cancer therapy, with a initial focus on lung, colon, and dermato-oncology. The firm said the funding will go towards expanding its team. More information »